LERN Stroke Pre-Hospital Destination Protocol – Educational Webinar


Sheryl Martin-Schild, MD, PhD, FANA, FAHA, FAAN Stroke Medical Director for Louisiana Emergency Response Network (LERN) Medical Director of Neurology & Stroke - Touro Infirmary Medical Director of Neurology & Stroke - New Orleans East Hospital President & CEO - Dr. Brain, Inc.



Why change the existing protocol?

STROKE DESTINATION PROTOCOL

The following protocol applies to patients with suspected stroke:



If < 15 minutes of additional transport time to reach CSC, TSC or endovascular capable Center (PSC-E), transfer to the CSC, TSC or endovascular capable Center (PSC-E) If > 15 minutes of additional transport time to reach CSC, TSC, PSC-E, PSC or ASRH than to reach stroke capable Off Site ED, it is acceptable to transport to a stroke capable Off Site ED

* the LSN < 6 hours should include patients without a definite time of LSN, but who could reasonably be assumed to be within 6 hours of onset, including patients who wake-up with stroke symptoms

Did not address:
LVO 6-24hrs from LSN
Stroke of

unknown time of onset

Management of LVO 6-24hrs from LSN

- DAWN
- DEFUSE-3



Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct


Dawn Trial

Type of stroke onset — no. (%)‡	Thrombectomy Group	Control Group
On awakening	67 (63)	47 (47)
Unwitnessed stroke	29 (27)	38 (38)
Witnessed stroke	11 (10)	14 (14)

Score on the Modified Rankin Scale




A Intention-to-Treat Population



Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging

DEFUSE 3 Trial

Stroke onset witnessed — no. (%)	Endovascular Therapy	Medical Therapy
Yes <u>†</u>	31 (34)	35 (39)
No		
Symptoms were present on awakening	49 (53)	42 (47)
Symptoms began during wakefulness	12 (13)	13 (14)



In routine clinical practice, what is the impact?

	o-6hr window	6-24hr window
Ν	238 (54.5%)	199 (45.5%)
CTA or MRA	221 (92.9%)	127 (63.8%)
LVO	82 (34.5%)	44 (22.1%)
thrombectomy	30 (12.6%)	8 (4%)
mRS = 2</td <td>11 (36.6%)</td> <td>4 (50%)</td>	11 (36.6%)	4 (50%)

Neuroradiology. 2021 Apr;63(4):603-607. doi: 10.1007/s00234-020-02531-8. Epub 2020 Sep 15.



Stroke of known time of onset

Time of onset of stroke is known when:
1) the patient is able to provide history
2) the onset of symptoms was witnessed

• When the time of onset of stroke is known,

 last seen normal (LSN) = time symptoms noted (TSN) = time of stroke onset (TSO)

Stroke of unknown time of onset

- Almost 33% of all patients with ischemic stroke have unknown time of stroke onset
 - Most have symptoms noted upon awakening
 - Others have unwitnessed stroke onset and the patient cannot provide a time of symptom onset

Historically, excluded from IV lytic

Thrombolytic therapy for patients who wake-up with stroke

<u>Andrew D Barreto¹</u>, <u>Sheryl Martin-Schild</u>, <u>Hen Hallevi</u>, <u>Miriam M Morales</u>, <u>Anitha T</u> <u>Abraham</u>, <u>Nicole R Gonzales</u>, <u>Kachi Illoh</u>, <u>James C Grotta</u>, <u>Sean I Savitz</u>

- Two symptomatic intracerebral hemorrhages occurred in treated WUS (4.3%).
- Adjusting for NIHSS imbalance, treated WUS had higher rates of excellent (14% vs 6%; P=0.06) and favorable outcome (28% vs 13%; P=0.006), but higher mortality (15% vs 0%) compared to nontreated WUS.
- A second comparison adjusting for baseline NIHSS between treated WUS and 174 intravenous tissue plasminogen activator patients treated within 3 hours of symptoms showed no significant differences in safety and clinical outcomes.

Stroke 2009 Mar;40(3):827-32. doi: 10.1161/STROKEAHA.108.528034. Epub 2009 Jan 8.

EMERGENCY RESPONSE NETWORK

MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset

The WAKE UP Trial – RCT IV alteplase vs placebo

- Stroke symptoms upon waking up, or were unable to report the time of onset, and it was at least 4.5 hours since LSN
- MRI showed an acute ischemic lesion on diffusion-weighted imaging but no parenchymal hyperintensity with standard window settings on FLAIR
- Excluded if hemorrhage (n=87)
- Excluded if >1/3 MCA territory on DWI (n=45)
- Excluded if thrombectomy planned (n=15)
- Excluded if NIHSS >25
- Excluded if standard contraindication to IV alteplase

The WAKE UP Trial: *Thomalla G, Simonsen CZ, Boutitie F, et al.* **MRI-Guided Thrombolysis** for Stroke with Unknown Time of Onset. The New England journal of medicine. 2018; 379(7):611-622. PMID: <u>29766770</u>

MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset

The WAKE UP Trial – RCT IV alteplase vs placebo

Of the 1362 patients screened:

- 455 were excluded for FLAIR lesion
- 137 were excluded because the DWI was negative
- The median NIHSS score on arrival was 6.
- 89% of patients had wake up strokes.
- The median time between symptoms noted and alteplase was 3.1 hours.
- The median time between LSN and alteplase was 10 hours.

MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset

The WAKE UP Trial – RCT IV alteplase vs placebo

Outcome	Alteplase Group (N=254)	Placebo Group (N=249)	Effect Variable	Adjusted Value (95% CI)†	P Value
Primary efficacy end point					
Favorable outcome at 90 days — no./total no. (%)‡	131/246 (53.3)	102/244 (41.8)	Odds ratio	1.61 (1.09 to 2.36)	0.02
Secondary efficacy end points					
Median score on modified Rankin scale at 90 days (IQR)§	1 (1-3)	2 (1-3)	Common odds ratio	1.62 (1.17 to 2.23)	0.003¶
Correlation between treatment re- sponse at 90 days and deficit level at baseline — no./total no. (%)	72/246 (29.3)	44/244 (18.0)	Odds ratio	1.88 (1.22 to 2.89)	0.004¶
Global Outcome Score at 90 days**			Odds ratio	1.47 (1.07 to 2.04)	0.02¶
Median score on Beck Depression Inventory at 90 days (IQR)††	6.0 (2.0–11.0)	7.0 (2.0–14.0)	Mean difference (log _e)	-0.04 (-0.22 to 0.15)	0.69¶
Total score on EQ-5D at 90 days‡‡	1.9±2.1	2.4±2.4	Mean difference	-0.52 (-0.88 to -0.16)	0.004¶
Score on visual analog scale on EQ-5D at 90 days∭	72.6±19.7)	64.9±23.8	Mean difference	7.64 (3.75 to 11.51)	<0.001¶
Median infarct volume at 22–36 hr (IQR) — ml ¶¶	3.0 (0.8–17.7)	3.3 (1.1–16.6)	Mean difference (log _e)	-0.16 (-0.47 to 0.15)	0.32¶

No safety concern

- 2.4% sICH (ns)
- NNT <9
- THAWS trial also
 used MRI, but low
 dose alteplase and
 terminated early
 with no difference
 in outcome

Intravenous thrombolytic treatment and endovascular thrombectomy for ischemic wake-up stroke (Review)

Summary of findings 1. Intravenous thrombolytic treatment compared to standard medical care for wake-up stroke

Intravenous thrombolytic treatment compared to standard medical care for wake-up stroke

Patient or population: people with stroke upon awakening Setting: hospital emergency department Intervention: intravenous thrombolytic treatment Comparison: standard medical care

Outcomes	Anticipated absolut	e effects [*] (95% CI)	Relative effect (95% CI)	No. of partici- pants	Certainty of the evidence
	Risk with stan- dard medical care	Risk with intravenous thrombolytic treatment	((studies)	(GRADE)
Independent functional outcome at end of fol- low-up assessed with: mRS 0 to 2 at follow-up: 90 days	584 per 1000	660 per 1000 (590 to 736)	RR 1.13 (1.01 to 1.26)	763 (5 RCTs)	⊕⊕⊕⊕ HIGH
Symptomatic intracranial haemorrhage at fol- low-up: mean 90 days	5 per 1000	19 per 1000 (5 to 67)	RR 3.47 (0.98 to 12.26)	754 (4 RCTs)	⊕⊕⊕⊕ HIGH
Death at follow-up: mean 90 days	99 per 1000	67 per 1000 (43 to 106)	RR 0.68 (0.43 to 1.07)	763 (5 RCTs)	⊕⊕⊕⊕ HIGH

Cochrane Database of Systematic Reviews 2021, Issue 12. Art. No.: CD010995

EXTEND trial

 4.5 – 9 hrs from onset or awakening with symptoms

 Perfusion lesion—ischemic core mismatch was defined as a ratio greater than 1.2 between the volume of hypoperfusion and the volume of the ischemic core, an absolute difference in volume greater than 10 ml, and an ischemic-core volume of less than 70 ml.


No plan for thrombectomy

Ta	ble	2.	Efficacy	and	Safet	y Outcomes.*
----	-----	----	----------	-----	-------	--------------

	Table 2. Efficacy and Safety Outcomes.*						
EX	Outcome	Alteplase (N=113)	Placebo (N=112)	Adjusted Effect Size (95% CI)†	P Value	Unadjusted Effect Size (95% CI)†	P Value
		no./total	no. (%)				
	Primary outcome						
	Score of 0 to 1 on the modified Rankin scale at 90 days‡	40/113 (35.4)	33/112 (29.5)	1.44 (1.01–2.06)	0.04	1.2 (0.82–1.76)	0.35
• 10	Secondary outcomes						
	Score on the modified Rankin scale at 90 days						
• 25	0	14/113 (12.4)	12/112 (10.7)				
	1	26/113 (23.0)	21/112 (18.8)				
• 25% • 65%	2	16/113 (14.2)	15/112 (13.4)				
• 05 X	3	15/113 (13.3)	16/112 (14.3)				
	4	15/113 (13.3)	24/112 (21.4)				
	5	14/113 (12.4)	14/112 (12.5)				
	6	13/113 (11.5)	10/112 (8.9)				
	Functional improvement§			1.55 (0.96–2.49)		1.18 (0.74–1.87)	
	Functional independence¶	56/113 (49.6)	48/112 (42.9)	1.36 (1.06–1.76)		1.16 (0.87–1.54)	
	Percentage of reperfusion at 24 hr						
	≥90%	53/106 (50.0)	31/109 (28.4)	1.73 (1.22–2.46)		1.76 (1.23–2.51)	
	≥50%	76/106 (71.7)	57/109 (52.3)	1.35 (1.09–1.67)		1.37 (1.10–1.70)	
	Tertiary outcomes						
	Recanalization at 24 hr	72/107 (67.3)	43/109 (39.4%)	1.68 (1.29–2.19)		1.71 (1.30–2.23)	
	Major neurologic improvement						
	At 24 hr	32/113 (28.3)	13/112 (11.6)	2.52 (1.40–4.56)		2.44 (1.35–4.40)	
	At 72 hr	41/112 (36.6)	25/112 (22.3)	1.70 (1.11–2.59)		1.64 (1.07–2.51)	
	At 90 days	56/101 (55.5)	56/99 (56.6)	1.02 (0.80–1.31)		0.98 (0.77–1.25)	
	Safety outcomes						
	Death within 90 days after intervention	13/113 (11.5)	10/112 (8.9)	1.17 (0.57–2.40)	0.67	1.29 (0.59–2.82)	0.53
	Symptomatic intracranial hemorrhage within 36 hr after intervention	7/113 (6.2)	1/112 (0.9)	7.22 (0.97–53.54)	0.053	6.94 (0.86–55.73)	0.07

WORK

EXTEND trial




Μ

Time				Placeb (n=15		Altepla (n=152		Odds rat (95% CI)		p value	
>4.	Primary outco	ome									
>6.(Wal	Excellent outco at 3 months	ome (mR	score 0–1)	39/15	1 (26%)	55/152	2 (36%)	2.06 (1.3	17-3.62)	0.012	
Image Image	Secondary ou	tcomes									
MRI Time	Functional im score at 3 mor		t in mRS	NA		NA		1.68 (1.3	11-2.53)	0.014	
of intr Time f initiat	Functional independence (mRS score 0-2) at 3 months		60/151 (40%)		77/152	77/152 (51%)		2-22 (1-25-3-94)			
Large Ischae	Early neurolog 72 h‡	ical impro	wement at	36/15	2 (24%)	58/14	8 (39%)	2.13 (1.2	28-3·51)	0.003	
imagi Perfus	Safety outcor	nes									
imagi	Death at 3 mo	nths		16/15	2 (11%)	20/152	2 (13%)	1.28 (0.	60-2.73)	0.52	
	Symptomatic haemorrhage		oral	1/15	2 (1%)	7/152	2 (5%)	7.29 (0.	88-60-18)	0-07	
	ò	10	20	30	40 P:	50 atients (%)	60	70	80	90	100
_						(//)					


3. In patients with AIS who awake with stroke symptoms or have unclear time of onset > 4.5 hours from last known well or at baseline state, MRI to identify diffusion-positive FLAIR-negative lesions can be useful for selecting those who can benefit from IV alteplase administration within 4.5 hours of stroke symptom recognition.	lla	B-R	New recommendation.
The WAKE-UP trial (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke) AIS who awoke with stroke or had unclear time of onset >4.5 hours from last known we alteplase within 4.5 hours of stroke symptom recognition. Eligibility required MRI misma on DW-MRI and no visible signal change on FLAIR. DW-MRI lesions larger than one-third cerebral artery (MCA), NIHSS score >25, contraindication to treatment with alteplase, or all exclusions. The trial was terminated early for lack of funding before the designated 8 Ninety-four percent were wake-up strokes. Median NIHSS score was 6. Median time from over 10 hours. At baseline, one-third of the patients had vessel occlusion on time-of-flig of the FLAIR lesions were <9 mL. The end point of an mRS score of 0 to 1 at 90 days we alteplase group and in 41.8% of the placebo group (P =0.02). ⁸⁸	ell and could be atch between al d of the territory planned throm 00 patients we om last known v ht MRA, and th	treated with IV boormal signal y of the middle bectomy were re randomized. well was slightly ree-quarters	See Table XIX in online Data Supplement 1

Patients with wake-up stroke should be evaluated with same urgency as a patient presenting within the window for IV alteplase, because those with DWI+/FLAIR- pattern can benefit from treatment.


New initial destination protocol for stroke





New initial destination protocol for stroke



New initial destination protocol for stroke










Hematoma expansion – time from onset of ICH

- Multivariate modeling of HEpredictors showed that the predicted probability for HE declined at increasing time from onset to diagnostic imaging.
- The decline was steepest between 0.5 and 3 h, indicating that HE is much more probable within the first 3 h.
- Ongoing bleeding beyond 4 hours of symptom onset is uncommon





Efficiency of advanced imaging to determine eligibility





• mean interval between CT and MRI of 1.83 h






Stroke Destination Protocol

- unanimously approved by the LERN Board on 11/16/2023
- protocol will go live on January 1, 2024
- LERN Communication Center (LCC) medics have received education
- LCC medics have practiced using the new Protocol
 - Destination recommendation changed in 6/237 cases

Where are the resources?



MRI 24/7 with tech call schedule for off hours and weekends

Region 4		Stroke Level	MRI	СТ	TeleStroke Hub	Endovaso	ular-Stroke	STEMI	Cath Lab Open	Facility Commen
Abbeville General Hospital Last updated on: 11/26/2023 12:16 AM		ASRH	Routine	Yes	Lourdes			Referral		Cardiology on c
CAcadia St. Landry Hospital • Last updated on: 04/17/2023 09:14 AM		SBH		Yes				Referral		
 Acadian Medical Center Last updated on: 09/27/2023 02:27 PM 		SBH	Routine	Yes	NA			Referral	No	
Iberia Medical Center Last updated on: 11/26/2023 02:02 AM	Definitions					×		Receiving	Yes	
Mercy Regional Medical Center Last updated on: 11/26/2023 06:24 AM	Demittion	5				^	No	Referral	No	
Ochsner Abrom Kaplan Memorial H Last updated on: 11/26/2023 04:52 AM	MRI						No	Referral	No	
Ochsner Acadia General Hospital Last updated on: 11/26/2023 06:53 AM	Definition: MIF		atus Defi	nitio	ns		-	Referral	-	Ortho & Urology
Ochsner Lafayette General Medica Last updated on: 11/26/2023 02:24 AM		No MRI	No MR				/es	Receiving	Yes	
Ochsner Lafayette General Orthop Last updated on: 11/26/2023 06:15 AM		Routine	Emerge	ent not	available			Referral		
Ochsner St. Martin Hospital • Last updated on: 11/23/2023 06:42 AM	E	mergent	MRI 24 hours a		n tech call schedule ekends	e for off	No	Referral	No	
Ochsner University Hospital and C Last updated on: 11/26/2023 06:44 AM		Азпіт	noutine	105	LOWIC			Referral	No	
Opelousas Gen. Health Sys-SouthCo Last updated on: 11/26/2023 07:26 AM	amp	ASRH	No MRI	Yes	Ochsner			Referral		
Opelousas General Health System Last updated on: 11/26/2023 07:26 AM		ASRH	Emergent	Yes	Ochsner		No	Receiving	Yes	
Our Lady of Lourdes Heart Hospital Last updated on: 11/26/2023 07:20 AM		ASRH	No MRI	Yes	Lourdes		No	Receiving	Yes	
Our Lady of Lourdes Regional Medie	cal Center Inc.	D 00-5	D	v		,	,	D · · ·	V	

New data requirements – Which hospitals?

• All PSCs, PSC-Es, TSCs, and CSCs

New data requirements – Which patients?

 Patients who present within 3.5 hrs. of time symptoms noted (TSN) who have an unknown time of stroke onset (TSO)


New data requirements – What variables?

- known Time of Stroke Onset (drop down with yes or no); centers with 24/7 endovascular services should ONLY include patients for whom the answer is no
- Last Seen Normal (military time) only if known, otherwise left blank; PSCs without 24/7 endovascular services are already providing this
- Time Symptoms Noted (military time)
- Arrival time at door (military time); PSCs without 24/7 endovascular services are already providing this
- - Mode of arrival; PSCs without 24/7 endovascular services are already providing this
- NIHSS; PSCs without 24/7 endovascular services are already providing this
- Imaging used to determine eligibility for IV lytic (drop down for CT, CTP, MRI)
- Time imaging for unknown stroke onset completed (military time)
- Time of IV lytic administration (military time)
- Reason why unknown stroke onset presenting <3.5 hours from Time Symptoms Noted was not treated with IV lytic (drop down with established stroke on CT, no/small penumbra on CTP, stroke on FLAIR, hemorrhage on imaging, stroke mimic, refusal, other standard IV lytic contraindication, arrived <3.5 hours but unable to treat <4.5 hours)

New data requirements – what are the goals?

- learn how patients with unknown time of stroke onset are being evaluated and treated
- establish benchmarks for ASRHs
- strive for a 45 minute turnaround time






	Q3/Q4 2022 data from PSC ALL <24hrs from LSN & LVO screen+ N=148	Q1/Q2 2023 data from PSC ALL <24hrs from LSN & LVO screen+ N=97	Q3/Q4 2022 data from ASRH ALL <24hrs from LSN N=2094	Q1/Q2 2023 data from ASRH ALL <24hrs from LSN N=2097
% arriving by ambulance	71.6% 106/148	74.2% 72/97	44.2% 925/2094	41.5% 861/2076
NIHSS, median (range), [IQR]	16 (0-39) [7-21] 139/148, 93.9%	13 (1-33) [6-18] 95/97, 97.9%	2 (0-44) [1-7] n=1880, 89.8% LVO+ 13 (0-44), [5-12], n=197 LVO – 2 (0-42), [1-6], n=1595	2 (0-42) [1-6] N=1984, 94.6%
% screened for LVO	100%	100%	93.3% 1893/2030	97.8% 1991/2035
Method of LVO screening	Not required of PSCs	Not required of PSCs	VAN, 50.9 CTA, 27.5 Both, 14.2 Other clinical, 6.1 Other vascular, 1.2	VAN, 51.9 CTA, 29.1 Both, 12.7 Other clinical, 5.2 Other vascular, 1.0
% LVO screen positive	100%	100%	11.1% 209/1888	9.2% 182/1983

	Q3/Q4 2022 data from	Q1/Q2 2023 data from	Q3/Q4 2022 data from	Q1/Q2 2023 data from
	PSC	PSC	ASRH	ASRH
	ALL <24hrs from LSN			
	& LVO screen+	& LVO screen+	N=2094	N=2097
	N=148	N=97		
Door in-Decision,	50 (0-700)	42 (4-171)	57 (0-269)	55 (0-356)
median (range)	[21 -100]	[27-63]	[32-97]	[30-90]
	N=107	N=95	N=133	N=114
Decision-to-transfer	3 (0-124)	o (o-76)	0 (0-103)	0 (0-209)
request, median (range)	[0-10]	[0-4]	[0-6]	[0-9]
	N=106	N=93	N=128	N=113
Door in-transfer	51 (1-710)	45 (4-187)	66 (5-455)	64 (0-374)
request, median	[31-103]	[30-64]	[39-112]	[35-108]
(range), [IQR] minutes	N=103	N=94	N=133	N=122
Transfer request-to-	(0-908)	14 (0-209)	20 (0-342)	28 (0-238)
Acceptance, median	[3-43]	[3-30]	[5-50]	[10-51]
(range)	N=98	N=92	N=135	N=119
Acceptance-to-EMS on	31 (0-270)	36 (0-177)	45 (0-476)	43 (0-177)
scene, median (range)	[16-50]	[12-60]	[34-65]	[27-64]
	N=66	N=52	N=97	N=92
EMS on scene-to-door	14 (0-451)	12 (0-55)	3 (0-67)	10 (0-113)
out, median (range)	[7-24]	[7-17]	[0-11]	[3-14]
	N=73	N=55	N=98	N=92
Acceptance-to-door	47 (0-310)	46 (7-186)	53 (0-476)	53 (6-186)
out, median (range)	[32-66]	[27-74]	[41-80]	[34-77]
	N=104	N=92	N=138	N=120
Transfer request-	66 (27-943)	66 (7-290)	78 (10-477)	88 (7-405)
departure, median	[48-96]	[42-99]	[59-133]	[59-125]
(range), [IQR] minutes	N=98	N=93	N=134	N=122
Door in-door out time,	131 (39-1284)	120 (32-328)	152 (50-711)	165 (55-481)
median (range), [IQR]	[95-224]	[88-164]	[115-244]	[120-226]
minutes	N=116	N=96	N=142	N=124
	20.7% met target	28.1%	9.9% met target	11.3% met target
				-

One example of successful DIDO remediation


Rapides DIDO Median





Orders CT/CTA Bundle Coordinator EDMD performs Patient arrives at CT 0-5 min contacts (CTP for wakeup or screen; assess with Stroke Team, Tulane Telestroke deficits; confirms stroke activation Level 2) CT completed s indicated Obtain B/P and pulse. If no exclusions, Lytic & EDMD brief hx; NIHSS, LKW and Level 1 or 2 B/P meds to CT CBS, start IV; Blood confirmed collected passed to Lab Level 1 Level 2 Level? 0 - < 6 ; wake up ≥ 6 - 24; unkno 5-10 min Request Direct Beam In. Patient to weight bed EDMD & Teleneuro Telephone consult EDMD to Teleneuro while consult per Robot with patient initiating additional imaging as indicated. assessment If VAN + Began Transfer Process CTA & CTP per image protocol CT Results per Robot or phone call 10-20 min EDMD 8 Teleneuro etermine Lyti eligible CTA/CTP per Give Lytic imaging protocol 20-30 min CT with hemorrhage present? **Results Called** Proceed to Hemorrhagic Stroke pathway. 30-45 min LVO 8 Intervention Can didate? Transfer per Admit transfer 60 min protocol





Questions?

Scene Town of Zachary North LA EBR EMS @06:27 EM-7 to LERN Stroke report

History of Presenting Condition

61 year old male @ 06:12 while eating breakfast experienced sudden onset slurring of speech, facial droop on his left with weakness in left side upper and lower limbs. His's wife Mary spotted these sudden onset of symptoms and immediately called for an ambulance, which arrived within 15 mins.

Pre-Hospital Assessment


Vitals: BP 140/90 mmHg Pulse 75 RR: 22 SpO2 98% RA GCS 14 CBG: 180 B.F.A.S.T Left Facial Droop Left Motor Weakness: Upper Limb no muscle activation, arm falling quickly. Lower Limb can move the limb, but unable to lift against gravity. Slurred Speech VAN Vision RT gaze preference Aphasia none Neglect can't fell touch on the left

Time of onset know?
What Is the TSO, LSN and TSN?
ETE to Lane 8 minutes
ETE to OLOL 30 minutes
LCC destination recommendation?
Apply the protocol



closest stroke facility

closest stroke facility



Hospital Management

CT

- Hyperdensity in the M1 Segment of the Right Middle Cerebral Artery, with no other signs suggestive of an Ischemic Stroke noted.
- Provisional diagnosis of Acute Ischemic Stroke secondary to occlusion of the M1 was made.
- Patient was treated with intravenous Tissue Plasminogen Activator (tPA).
- Transferred to OLOL Endovascular Thrombectomy Initiated at 3hr

Scene Town of Lake Charles LA AASI @09:10 U-401 to LERN Stroke report

History of Presenting Condition

58 year old male old male awoke at 6:00 and was at work by 7:00. Co-workers had witnessed patient and seemed normal that AM. Found sitting on a pallet at 9:00 and when co-worker attempted to find out what was wrong –co-worker questioned patient and speech was gibberish, he noted left sided facial droop and arm weakness.

911 called Co-worker notified wife

Pre-Hospital Assessment


Vitals: BP 160/100 mmHg Pulse 80 RR: 20 SpO2 97% RA GCS 13 CBG: 98 No blood thinners B.F.A.S.T Left Facial Droop Left Motor Weakness: Upper Limb no muscle activation, arm falling quickly. Lower Limb can move the limb, but unable to lift against gravity. Slurred Speech VAN Vision RT gaze preference Aphasia cannot follow commands Neglect normal

Time of onset know?
What Is the TSO, LSN and TSN?
LCC destination recommendation?
Apply the protocol





STROKE DESTINATION PROTOCOL



Hospital Management

CT

Negative

NIH 13

Patient was treated with intravenous Alteplase NIH remained 13 and high suspicion of LVO. CT perfusion CT angio

Transferred to Lourdes for Endovascular Thrombectomy Upon arrival NIHSS –16

Scene Town of LaPlace LA AASI @07:30 U-62 to LERN Stroke report

History of Presenting Condition

63 year old right handed male, went to bed at 10pm. Patient did not show up to work who notified daughter at 0700 and she went to house and found father in bed with stroke symptoms (dysarthria , left hemiplegia and right gaze preference)

Pre-Hospital Assessment


Vitals: BP 188/110 mmHg Pulse 72 RR: 18 SpO2 98% RA GCS 13 CBG: 98 No blood thinners B.F.A.S.T Dysarthria Left Facial Droop Left Motor hemiplegia: Upper Limb no muscle activation, arm falling quickly. Lower Limb unable to lift against gravity. VAN Vision RT gaze preference Aphasia cannot follow commands Neglect normal

Time of onset know?
What Is the TSO, LSN and TSN?
LCC destination recommendation?
Apply the protocol





STROKE DESTINATION PROTOCOL



Hospital Management

CT Negative NIH 13 Patient was treated with intravenous Alteplase NIH remained 13 and high suspicion of LVO. CT perfusion CT angio Admitted for thrombectomy

Scene Town of Jennings, LA AASI @08:40 U-28 to LERN Stroke report

History of Presenting Condition

72 year old male, went to bed at 9pm and had spoken to his son on the phone. Patient did not answer phone at 0800 and son went to house and found father in bed with stroke symptoms @0830. Father is able to report he got week on the left side could not get out of bed and had a headache shortly after awaking @0700.


Pre-Hospital Assessment

Vitals: BP 158/98 mmHg Pulse 68 RR: 16 SpO2 95% RA GCS 15 CBG: 110 No blood thinners B.F.A.S.T Slurred speech Left Facial Droop Left Motor hemiparesis: Upper Limb mild drift. Lower Limb able to lift against gravity but also week. VAN negative

Time of onset know?
What Is the TSO, LSN and TSN?
LCC destination recommendation?
Apply the protocol







Hospital Management

LCC notified acute VAN negative stroke Upon arrival NIHSS –16 CT Old lacunar on the right Patient not a candidate for IV lytic. CT perfusion CT angio and admitted to hospital.

Scene Town of Alexandria LA AASI @15:32 U-210 to LERN Stroke report

History of Presenting Condition

59-year-old Hispanic man presented with right upper and lower extremity weakness, associated with facial drop and slurred speech. Patient had breakfast with family at 8:30. They dropped him off at home at 9:30. Family called 911 at 3:00PM. Patient denied visual disturbance, headache, chest pain, palpitations, dyspnea, dysphagia, fever, dizziness, loss of consciousness, bowel or urinary incontinence, or trauma.

Pre-Hospital Assessment


Vitals: BP 184/102 mmHg Pulse 80 RR: 18 SpO2 97% RA GCS 15 CBG: 90 No blood thinners B.F.A.S.T VAN negative



- Time of onset know?
- What Is the TSO, LSN and TSN?
- LCC destination recommendation?
- Apply the protocol



STROKE DESTINATION PROTOCOL



- Hospital Management
 Upon arrival NIHSS –7
 CT
 - Initial CT angiogram of head and neck reported no acute intracranial findings
 - MRI of the head revealed an acute 1.7-cm infarct of the left periventricular white matter and posterior left basal ganglia.